SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
SEC Accession No. 0001193125-21-043563
Filing Date
2021-02-16
Accepted
2021-02-16 08:32:51
Documents
2
Group Members
ANSBERT GADICKEMPM ONCOLOGY IMPACT MANAGEMENT GP LLCMPM ONCOLOGY IMPACT MANAGEMENT LPONCOLOGY IMPACT FUND (CAYMAN) MANAGEMENT L.P.

Document Format Files

Seq Description Document Type Size
1 SC 13G/A d125147dsc13ga.htm SC 13G/A 104701
2 EX-99.A d125147dex99a.htm EX-99.A 9443
  Complete submission text file 0001193125-21-043563.txt   115914
Mailing Address 11455 EL CAMINO REAL SUITE 250 SAN DIEGO CA 92130
Business Address 11455 EL CAMINO REAL SUITE 250 SAN DIEGO CA 92130 858-369-7100
MEI Pharma, Inc. (Subject) CIK: 0001262104 (see all company filings)

IRS No.: 510407811 | State of Incorp.: DE | Fiscal Year End: 0630
Type: SC 13G/A | Act: 34 | File No.: 005-79594 | Film No.: 21632844
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences

Mailing Address 450 KENDALL STREET CAMBRIDGE MA 02142
Business Address 450 KENDALL STREET CAMBRIDGE MA 02142 617-425-9200
UBS Oncology Impact Fund L.P. (Filed by) CIK: 0001691428 (see all company filings)

IRS No.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SC 13G/A